Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
出版年份 2013 全文链接
标题
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
作者
关键词
-
出版物
PLoS One
Volume 8, Issue 1, Pages e55818
出版商
Public Library of Science (PLoS)
发表日期
2013-02-01
DOI
10.1371/journal.pone.0055818
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes
- (2014) J. H. Rowe et al. JOURNAL OF IMMUNOLOGY
- Nitric oxide metabolites and arginase I levels in β-thalassemic patients: an Egyptian study
- (2012) Samy B. M. El-Hady et al. ANNALS OF HEMATOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Indoleamine 2,3-Dioxygenase and Arginase Type I May Contribute to Decreased Blood T-Cell Count in Hemodialysis Patients
- (2012) Theodoros Eleftheriadis et al. RENAL FAILURE
- Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer
- (2012) Zhi-Jun Jiao WORLD JOURNAL OF GASTROENTEROLOGY
- The role of the PD-1 pathway in autoimmunity and peripheral tolerance
- (2011) Brian T. Fife et al. Annals of the New York Academy of Sciences
- Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma
- (2011) Martin Loos et al. ANNALS OF THORACIC SURGERY
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
- (2011) J. Hasford et al. BLOOD
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
- (2011) B. Raychaudhuri et al. NEURO-ONCOLOGY
- Overall survival and PD-L1 expression in metastasized malignant melanoma
- (2010) Jules Gadiot et al. CANCER
- Clinical significance of B7-H1(PD-L1)expression in human acute leukemia
- (2010) Xiangli Chen et al. CANCER BIOLOGY & THERAPY
- Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign
- (2010) Isabel Poschke et al. CANCER RESEARCH
- Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
- (2010) S. Nagaraj et al. CLINICAL CANCER RESEARCH
- T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies
- (2010) Camilla A. Lindqvist et al. IMMUNOLOGY
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression
- (2009) S. Mumprecht et al. BLOOD
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- IL4Rα + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients
- (2009) Susanna Mandruzzato et al. JOURNAL OF IMMUNOLOGY
- Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34+CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy
- (2009) S Mustjoki et al. LEUKEMIA
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy
- (2008) D. Ennishi et al. ANNALS OF ONCOLOGY
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma
- (2008) S. Kusmartsev et al. CLINICAL CANCER RESEARCH
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)
- (2008) Jun-ichi Kitagawa et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer
- (2007) Stefanie Gross et al. IMMUNOLOGY LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search